Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients
Status:
Completed
Trial end date:
2020-05-25
Target enrollment:
Participant gender:
Summary
Multicentric, phase II neoadjuvant trial in hormone-positive, HER-negative, luminal B,
premenopausal breast cancer patients stage II-IIIA. Patients receive as neoadjuvant treatment
before surgery: three courses of anthracycline-based chemotherapy followed by exemestane p.o.
daily plus nivolumab i.v. 2-weekly for 8 courses. GnRH analogues are started concomitantly
with chemotherapy and maintained until the completion of neoadjuvant treatment.